How much do 68Ga-, 177Lu- and 131I-based radiopharmaceuticals contribute to the global radiation exposure of nuclear medicine staff?
L. Struelens,E. Aalbersberg,L. Beels,N. Cherbuin,Y. D’Asseler,F. De Monte,A. Lopez Medina,M. del Carmen Riveira Martin,W. Schoonjans,C. Terwinghe,S. Van den Block,F. Vanhavere,H. Zaidi,V. Schelfhout
DOI: https://doi.org/10.1186/s40658-024-00695-3
2024-11-20
EJNMMI Physics
Abstract:The radiation exposure of nuclear medicine personnel, especially concerning extremity doses, has been a significant focus over the past two decades. This study addresses the evolving practice of NM, particularly with the rise of radionuclide therapy and theranostic procedures, which involve a variety of radionuclides such as 68 Ga, 177 Lu, and 131 I. Traditional studies have concentrated on common radioisotopes like 99m Tc, 18 F, and 90 Y, but there is limited data on these radionuclides, which are more and more frequently used. This study, part of the European SINFONIA project, aims to fill this gap by providing new dosimetry data through a multicenter approach. The research monitors extremity doses to hands, eye lens doses, and whole-body doses in nuclear medicine staff handling 68 Ga, 177 Lu, and 131 I. It examines the type of activities performed and the protective measures used. The study extrapolates measured doses to annual doses, comparing them with annual dose limits, and assesses the contribution of these specific procedures to the overall occupational dose of nuclear medicine personnel.
radiology, nuclear medicine & medical imaging